By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Illumina has scheduled its annual shareholders meeting for April 18, during which the fate of Roche's $5.7 billion hostile bid for Illumina could be determined.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.